Removal of RNA-binding protein improves leukaemia survival
Study shows that removing the protein IGF2BP3 slows cancer growth and increases chances of survival of rare types of leukaemia in mice.
List view / Grid view
Study shows that removing the protein IGF2BP3 slows cancer growth and increases chances of survival of rare types of leukaemia in mice.
An experimental drug suggests that therapy for currently untreatable cases of cystic fibrosis is “clearly achievable”.
A new computer algorithm has identified highly conserved sequences in viral proteins that could make the best drug targets for COVID-19.
Researchers in Germany have identified 69 small molecules as binding partners for genomic RNA of SARS-CoV-2, possibly leading to new drugs.
In this article, Dr Jim Burns discusses promising pre-clinical results of how a new platform could treat the root cause of many devastating genetic diseases including myotonic dystrophy type 1.
In cell cultures, a compound named STM2457 was shown to interfere with coronavirus replication, making it a potential treatment for SARS-CoV-2.
A new mRNA-based vaccine has demonstrated success at protecting against multiple coronaviruses in pre-clinical studies.
Chemical synthesis of guide RNAs for CRISPR-Cas9 gene editing enables accurate and rapid production of CRISPR libraries and screening in an arrayed, one-gene-per-well fashion.
A new mRNA vaccine based on the malaria circumsporozoite protein was shown to elicit a robust immune response in mice.
For the first time, scientists have found evidence that polymerase theta can write RNA segments back into DNA.
Researchers have created an algorithm that can predict the efficiencies of guide RNAs for CRISPR, potentially making it more precise.
A new method named scifi-RNA-seq marks the RNA of cells with specific barcodes, enabling the sequencing of many cells at the same time.
Scientists have created a RT-ddPCR assay to analyse both the non-coding and coding RNA regions of SARS-CoV-2.
Researchers have explored the interaction between SARS-CoV-2 RNA and the host cell, uncovering possible targets to prevent viral replication.
Scientists have created an antiviral therapy using lipid nanoparticles that deliver siRNA to the lungs to treat COVID-19 in mice.